Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Merck

Foreign exchange and Consumer Care divestiture impact results

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck
 
2Q Revenues: $9.8 billion (-11%)

2Q Earnings: $687 million (earnings were $2 billion 2Q14)

YTD Revenues: $19.2 billion (-9%)

YTD Earnings: $1.6 billion (-56%)

Comments: Pharmaceutical sales were $8.6 billion, down 6% in the quarter. JANUVIA sales were $1.6 billion, up 1%. ZETIA / VYTORIN sales were down 16% to $955 million. GARDASIL sales were up 4% to $427 million. ISENTRESS sales dropped 17% to $375 million due to timing of tender purchases in the emerging markets and volume declines in the U.S. R&D expenses were $1.6 billion in the quarter, down 2%. Results include a 7% negative impact from foreign exchange and a 7% unfavorable impact from the divestiture of the Consumer Care business, partially offset by the acquisition of Cubist Pharmaceuticals.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters